Like i said before, i've never known BOCX to leave a gap unfilled and there is still a nice open gap 80-90c. we may base in the 80's and even touch back to the 70's on no news, but i firmly believe BOCX is a winner and will run when least expected.
1.) If Abbott were able to ink an exclusive agreement with Biocurex, why would they license the technology to their competitors. I just don't see Biocurex giving Abbott full control of their technology.
2.) How does Abbott incorporate a new FDA approved test into the analyzers already in use. Do the hospital's/labs purchase an upgrade at an additional cost.
News 
Market Data 
Discover 
